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Abstract 
We describe a rare case of adult T-cell leukemia characterized by an expansion of CD4+ 
CD8+ double-positive lymphocytes associated with human T-lymphotropic virus type 1 
(HTLV-1) and a complex karyotype in a 43-year-old Caribbean male who was initially 
admitted to our hospital with significant lethargy, visual disturbances, dysphagia, right 
facial palsy and numbness in both feet for 3 days. He was found to have severe 
hypercalcemia (15.6 mg/dl). Peripheral blood smear showed multilobulated clover-
shaped nuclei. Bone marrow and CSF flow cytometries revealed abnormal monoclonal 
expansion of T cells positive for CD4, CD5, CD8 and CD25 but negative for CD7, CD20, 
CD56, CD68 and terminal deoxynucleotidyl transferase. The polymerase chain reaction 
analysis showed a distinct band of the T-cell receptor γ gene, revealing T-cell clonal 
integration of the proviral DNA of HTLV-1, thus confirming the diagnosis of acute adult 
T-cell leukemia/lymphoma. Cytogenetic study revealed a male karyotype with 
monosomy 12, unbalanced translocation 5q and 13q and additional material on 5q, 7q, 
14q and 17q. The patient underwent prednisone (EPOCH) chemotherapy followed by 
autologous transplantation with BEAM regimen. Although patients with a rare mixed 
CD4+ CD8+ immunophenotype usually present with an aggressive clinical course and 
have a poor prognosis, our patient was able to survive for 2.5 years. 
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Background 
Adult T-cell leukemia/lymphoma (ATLL) is an aggressive type of leukemia/lymphoma 
associated with the human T-cell lymphotropic virus type 1 (HTLV-1) that is 
characterized by a short survival time and a poor response to chemotherapy [1]. There are 
several clinical subtypes of ATLL, namely an acute, lymphomatous, chronic, smoldering, 
and a rare cutaneous type [2, 3]. The disease is most frequently associated with a mature 
CD4+ CD8− T-cell phenotype. However, rare cases of an unusual form of 
immunophenotype characterized by co-expression of CD4+ CD8+ double-positive cells 
have been reported [4–7]. Isolated case reports have suggested a median survival time of 
about 6–8 months despite intensive treatment. Characteristic clinical features include 
high white-cell counts, skin lesions, hepatosplenomegaly, lymphadenopathy and 
hypercalcemia. Here, we report a rare case of dual CD4+ CD8+ double-positive ATLL 
with complex cytogenetic characteristics and discuss the clinical presentation and the 
course of this rare disease. 
Case Report 
A 43-year-old Caribbean male presented with a 3-day history of generalized body aches, weakness, 
myalgia, visual disturbances, dysphagia, constipation, and numbness in both feet. His past medical 
history was significant for hypertension and childhood infection of strongyloidiasis. Physical 
examination disclosed significant lethargy, malaise, uveitis in both eyes and, interestingly, right facial 
palsy. Routine laboratory test revealed a white blood cell count of 7,300/mm
3, hemoglobin 10.4 mg/dl, 
hematocrit 31.3%, platelet 477,000/mm
3, absolute neutrophil count 2,560 L, lymphocytes 5,500/mm
3, 
serum calcium 15.6 mg/dl, serum albumin 3.9 g/dl, blood urea nitrogen 26 mg/dl, and serum creatinine 
2.1 mg/dl. Other laboratory tests, including liver function tests, urine analysis, parathyroid hormone 
(PTH), parathyroid hormone related peptide (PTHrp), vitamin D3, angiotensin converting enzyme, 
serum protein electrophoresis, urine protein electrophoresis, serum immunoglobulins and 
immunofixation were within normal limits. Neuroimaging was unremarkable. Examination of 
peripheral smear revealed presence of abnormal lymphocytes with multilobulated clover-shaped nuclei. 
Computed tomography scans of the abdomen and pelvis showed a multifocal mass and enlargement of 
the liver and spleen. No enlargement of the periaortic, iliac or inguinal lymph nodes was observed. 
Serum antibodies against HTLV-1 (gp19, gp21) were found to be positive and negative for HIV. Bone 
marrow flow cytometric analysis also revealed 49% abnormal clones of T cells positive for CD2, CD4, 
CD5, CD8, CD25, CD38 and CD45 and non-immunoreactive for CD7, CD20, CD34, CD56, CD117, 
HLA-DR and terminal deoxynucleotidyl transferase. Cerebral spinal fluid flow cytometry confirmed 
similar findings with presence of clonal T cells positive for CD2, CD3, CD4, CD5, CD8 and CD25 and 
negative for CD7. Bone marrow cytogenic study showed a complex male karyotype of 47,XY with 
several numeric and structural abnormalities involving the long arm of chromosomes 1, 3, 6, 7, 12, 13, 
and 14q32, as well as the short arm of chromosomes 10, 17, and 21. We also noticed monosomy of 
chromosome 12 and unbalanced translocation on the long arm of chromosomes 5 and 13, additional 
material on the long arm of chromosomes 5, 7, 12, 14 (14q+ chromosome) and 17, and on the short arm 
of 2 of the 3 copies of chromosome 4 as well as a marker chromosome in 16 of 20 metaphases, 
suggesting a partial trisomy or inactive genetic material. Finally, rearrangement of the T-cell receptor γ 
(TCRγ) gene located on chromosome 7 was tested to analyze the clonality in T-cell 
lymphoproliferations amplified by fluorescent polymerase chain reaction (PCR), which showed a 
distinct band of the TCRγ gene, revealing T-cell clonal integration of proviral DNA of HTLV-1, thus 
confirming the diagnosis of acute ATLL. 
The patient was given a chemotherapy regimen of etoposide, vincristine, doxorubicin, 
cyclophosphamide and prednisone (EPOCH) along with aggressive management of hypercalcemia 
using hydration, bisphosphonates and calcitonin. Repeated flow cytometry after the 3rd cycle of the 
EPOCH regimen showed no abnormal phenotype in the bone marrow. However, after the 5th cycle of 
the EPOCH regimen, an Ommaya tap was done that revealed Candida species. The patient then 
underwent successful autologous stem cell transplantation with high-dose BEAM. Repeated bone  
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marrow aspirate and biopsy 9 months after transplantation demonstrated no evidence of lymphoma 
and T-cell band, T-cell γ and T-cell δ, nor an abnormal phenotype on flow cytometry. However, after 13 
months of autologous stem cell transplantation, the patient relapsed and was admitted to the hospital 
with refractory hypercalcemia. Salvage regimen which included gemcitabine and vinorelbine was 
started. Unfortunately, the response to the treatment was poor and a hyper-CVAD regimen (i.e., a high 
dose of methotrexate and a high dose of cytarabine) was introduced with rapid resolution of 
hypercalcemia and white cell count. However, disease recurred again with refractory hypercalcemia 
after 3 months, being complicated by disseminated infection requiring antibacterial, antiviral and 
antifungal agents. Overall, the patient survived for 25 months from the time of diagnosis and 17 months 
after transplantation. 
Discussion 
We have reported a rare case of expansion of a CD4+ CD8+ double-positive cell 
population in a Caribbean male with a complex male karyotype, infected with HTLV-1. 
The disease was first described in Kyushu, in southwestern Japan, and it occurs most 
frequently in endemic areas such as Japan, the Caribbean basin, West Africa, Brazil, 
Central and South America and northern Iran [2, 4]. The disease is considered a fatal 
malignant post-thymic lymphoproliferative disorder and is characterized by the presence 
of leukemic cells with highly convoluted nuclei (so-called ‘flower-like cells’), 
lymphadenopathy, hepatosplenomegaly, skin lesions, and hypercalcemia. 
The involvement of CD4+ cells in the development of ATLL is indisputable; however, 
few case reports have noticed an unusual phenotype of double-positive CD4+ and CD8+ 
expression in patients with an extremely aggressive course. 
Kim et al. [8] reported an extremely aggressive course with poor survival in a patient 
with CD4+ CD8+ double-positive acute adult T-cell leukemia with skin manifestations. 
Kamihira et al. [7] reported a poorer prognosis with a median survival of 7.8 months as 
compared to patients with the typical CD4– CD8– phenotype. Ciminale et al. [9] describe 
a CD4+ CD8+ phenotype acute lymphoma in a Greek patient with an aggressive clinical 
course of refractory hypercalcemia. Several authors have implicated a high proliferation 
index (>18%), and large cells are suggestive of a poor prognosis in these patients [10]. 
Although HTLV-1 infects both CD4+ and CD8+ T cells, leukemogenic potential of the 
virus is restricted to the CD4+ subset. The dynamic relationship between the 
co-expansion of two cell populations of CD4+ and CD8+ in the course of the disease is 
still unclear. However, since the CD4/CD8 double-positive phenotype is characteristically 
associated with the majority of immature thymic precursors, it is hypothesized that the 
infection with HTLV-1 and expansion of CD8+ cells plays a helper role in the selection of 
specific CD4+ cell clones, and thus, during intrathymic ontogeny, immature CD4+/CD8+ 
thymocytes develop into functionally competent CD3+/CD4+/CD8– or CD3+/CD4–
/CD8+ T cells after transient expression of the CD4/CD8 double-positive phenotype [11]. 
Sibon et al. [12] have shown that infected CD4+ and CD8+ cells displayed the same 
pattern of clonal expansion in vivo, and both subsets of T cells disseminated the virus at a 
proviral state, although the degree of clonal expansion was higher in CD4+ than in CD8+ 
lymphocytes, which accounted for the significantly higher proviral loads harbored by the 
CD4+ subset of T cells. Alternatively, the viral infection may alter the expression of 
interleukin-4, which can modulate the expression of CD8 on the surface of CD4+ T cells, 
resulting in a concomitant expression of both markers [13].  
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Another possible mechanism includes clonal expansion of a less differentiated cell 
population which is immortalized by HTLV-1 infection; however, the finding that 
terminal deoxynucleotidyl transferase, which is a marker for thymic T-cell precursors, is 
usually not expressed in the infiltrative tumor cells opposes this hypothesis [7, 11–13]. 
One of the distinct features of the disease is refractory hypercalcemia, which requires 
frequent hospitalization and aggressive hydration. This phenomenon has been studied 
previously by Prager et al. [14] and other study groups [15–19]. They have shown 
increased bone resorption mediated by parathyroid hormone-related protein (PTHrP), 
transactivated by the HTLV-1 tax and HTLV-11 tax proteins, which mediates its effects 
on PTHrP via cellular transcription factors activator protein (AP)-2 and AP-1. 
Transactivation via an AP-2 motif represents a novel interaction of tax with a cellular 
transcription factor or lymphokines such as interleukin 1 (IL-1), IL-2, IL-6 and tumor 
necrosis factor (TNF), and dysregulation of cellular gene transcription by viral proteins. 
Interestingly, the hypercalcemia in our patient occurred in the setting of normal PTHrP 
and low 1,25(OH)2D levels, supporting the role for cytokines in the development of 
HTLV-1-related hypercalcemia [20]. 
Another interesting feature are the clonal chromosome abnormalities along with 
clinical heterogeneity and a plethora of secondary abnormalities in our patient. 
Interestingly, we noticed a hyperdiploid male karyotype, monosomy of chromosome 12 
and an unbalanced translocation on the long arm of chromosomes 5 and 13, additional 
material on the long arm of chromosomes 5, 7, 12, 14 (14q+ chromosome) and 17 and on 
the short arm of 2 of the 3 copies of chromosome 4, and a marker chromosome in 16 of 
20 metaphases, suggesting a partial trisomy or inactive genetic material. Five of these 
metaphases also showed a second copy of the marker chromosome. Interestingly, only 4 
metaphases showed a normal karyotype. Complex cytogenetic characteristics are 
presented in fig. 1. 
Itoyama et al. [21] reveal cytogenetic findings in 50 cases of ATLL where multiple 
breaks (at least 6), abnormalities of chromosomes 1p, 1p22, 1q, 1q10–21, 2q, 3q, 3q10–12, 
3q21, 14q, 14q32 and 17q, and partial loss of chromosomes 2q, 9p, 14p, 14q and 17q 
regions correlated with shorter survival [19]. The most frequent gains include trisomy 3, 
trisomy 8, trisomy 9 and trisomy 21. Monosomies involve chromosomes 4, 8, 10 and 22. 
Several authors have also suggested that 14q32 translocations were the most common 
abnormalities and are consistently observed in human T-cell tumors [22, 23]. To date, 
this is the only report which showed monosomy of chromosome 12 and complex 
cytogenetic chromosomal abnormalities with a male karyotype in HTLV-1 CD4+ CD8+ 
double-positive lymphoma.  
We believe that despite the aggressive course of the disease, the current treatment has 
allowed the patient to live longer. We used EPOCH chemotherapy with a 4-day infusion 
schedule of cyclophosphamide, vincristine, doxorubicin and etoposide, followed by 
antiretroviral therapy and successful autologous bone marrow transplantation with 
BEAM therapy. The patient remained in complete remission for 13 months after bone 
marrow transplantation with no evidence of recurrent HTLV-1 infection on PCR testing 
and on flow cytometry. However, salvage regimen which included gemcitabine and 
vinorelbine and, later on, hyper-cyclophosphamide, vincristine, adriamycin and 
dexamethasone resulted in a transient response after relapse.  
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In conclusion, we have shown that double-positive ATLL is an aggressive form of 
lymphoma associated with refractory hypercalcemia. Despite recent advances in 
treatment, information about this rare disease is still limited. In connection with the 
multiple chromosomal aberrations and complex cytogenetic characteristics observed in 
our patient, further investigation into the role of HTLV-1 in these lymphomas and 
clinical trials are warranted. 
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Fig. 1. Complex cytogenetic characteristics with multiple chromosomal aberrations. 
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